Johnson & Johnson to Acquire Firefly Bio for $1B
Johnson & Johnson (JNJ) entered into a definitive agreement on June 8, 2026 to acquire Firefly Bio for $1B in cash. The deal aims to strengthen JNJ's oncology portfolio with Firefly's Firelink degrader antibody conjugate platform targeting KRAS-driven tumors.
Key Numbers
Johnson & Johnson (NYSE:JNJ) announced on June 8, 2026 that it has entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. The acquisition is intended to bolster JNJ's oncology capabilities through Firefly's proprietary Firelink platform.
Deal Details
| Item | Value |
|---|---|
| Deal Value | $1 billion in cash |
| Target | Firefly Bio |
| Payment Method | All cash |
| Expected Close | Not yet announced |
Rationale
Firefly Bio specializes in developing the Firelink degrader antibody conjugate platform, which targets KRAS-driven tumors. KRAS is one of the most common oncogenes and has historically been difficult to target. The acquisition positions JNJ to advance novel therapies for solid tumors.
Regulatory Challenges
The deal is subject to regulatory approvals, including from the Committee on Foreign Investment in the United States (CFIUS) and antitrust authorities. No significant obstacles have been disclosed.
Impact on Stock
JNJ's stock showed no major reaction following the announcement. Analysts view the acquisition as a strategic move to strengthen JNJ's oncology pipeline, which could support long-term growth if the platform succeeds in clinical trials.
Frequently Asked Questions
Found this useful? Share it